AbbVie Inc. Return on Tangible Assets

Return on Tangible Assets of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Return on Tangible Assets growth rates and interactive chart.

Highlights and Quick Summary

  • Annual Return on Tangible Assets for 2019 was 21.36% (a -90.28% decrease from previous year)
  • Annual Return on Tangible Assets for 2018 was 219.66% (a 205.55% increase from previous year)
  • Annual Return on Tangible Assets for 2017 was 71.89% (a 8.81% increase from previous year)
  • Twelve month Return on Tangible Assets ending September 29, 2020 was 193.52% (a -57.77% decrease compared to previous quarter)
  • Twelve month trailing Return on Tangible Assets increased by 805.99% year-over-year
Trailing Return on Tangible Assets for the last four month:
29 Sep '20 29 Jun '20 30 Mar '20 30 Dec '19
193.52% 458.3% 22.06% 21.36%
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Return on Tangible Assets of AbbVie Inc.

Most recent Return on Tangible Assetsof ABBV including historical data for past 10 years.

Interactive Chart of Return on Tangible Assets of AbbVie Inc.

AbbVie Inc. Return on Tangible Assets for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 21.36%
2018 219.66%
2017 71.89%
2016 66.07%
2015 64.42%
2014 24.73%
2013 31.11%
2012 48.73%
2011 95.33%
2010 61.31%

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Frontier Medicines, Corp.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.